Cutaneous T-cell lymphoma (CTCL) is a rare type of cancer, and its prevalence has been increasing in recent years. The lack of curative treatments makes this cancer critical in terms of diagnosis and treatment. The two main types of treatment are skin-directed and systemic therapies, with limitations related to adverse effects. Accordingly, there is a need for localized, non-invasive approaches that reduce systemic toxicity. To achieve this, nanotechnology has been explored to deliver safe, appropriate diagnosis and treatment. Gold nanoparticles (AuNPs) and transdermal patches containing AuNPs have shown great promise in the treatment of CTCL with a high safety profile. In this review, the pathophysiology of CTCL and its treatment modalities using AuNPs and transdermal patches are presented from both materials science and clinical perspectives.

1. Bagherani N, Smoller BR. An overview of cutaneous T cell lymphomas [version 1; peer review: 2 approved]. F1000Res. 2016;5:1882. doi: 10.12688/f1000research.8829.1

2. DeSimone JA, Sodha P, Ignatova D, et al. Recent advances in primary cutaneous T-cell lymphoma. Curr Opin Oncol. 2015;27(2):128-133. doi: 10.1097/CCO.0000000000000161

3. Burg G, Dummer R, Dommann S, et al. Pathology of cutaneous T-cell lymphoma. Hematol Oncol Clin North Am. 1995;9(5):961-995.

4. Dummer R, Vermeer MH, Scarisbrick JJ, et al. Cutaneous T cell lymphoma. Nat Rev Dis Primers. 2021;7(1):61. doi: 10.1038/s41572-021-00296-9

5. Semenov YR, Rosenberg AR, Herbosa C, et al. Health-related quality of life and economic implications of cutaneous T-cell lymphoma. Br J Dermatol. 2020;182(1):190-196. doi: 10.1111/bjd.17941

6. Silva GA. Introduction to nanotechnology and its applications to medicine. Surg Neurol. 2004;61(3):216-220. doi: 10.1016/j.surneu.2003.09.036

7. Sahoo SK, Parveen S, Panda JJ. The present and future of nanotechnology in human health care. Nanomedicine. 2007;3(1):20-31. doi: 10.1016/j.nano.2006.11.008

8. Hossain A, Rayhan TM, Mobarak HM, et al. Advances and significance of gold nanoparticles in cancer treatment: A comprehensive review. Res Chem. 2024;8(2):101559. doi: 10.1016/j.rechem.2024.101559

9. Swallow MA, Micevic G, Zhou A, et al. Clinical and histologic variants of CD8+ cutaneous T-cell lymphomas. Cancers. 2024;16(17):3087. doi: 10.3390/cancers16173087

10. De Masson A, Lazaridou I, Moins-Teisserenc H, et al. Pathophysiology of cutaneous T-cell lymphomas: perspective from a French referral centre. Immunol Lett. 2024;268:106871. doi: 10.1016/j.imlet.2024.106871

11. Ni Z, Walcheck B. Cutaneous lymphocyte-associated antigen (CLA) T cells up-regulate P-selectin ligand expression upon their activation. Clin Immunol. 2009;133(2):257-264. doi: 10.1016/j.clim.2009.07.010

12. Ferenczi K, Fuhlbrigge RC, Pinkus J, et al. Increased CCR4 expression in cutaneous T cell lymphoma. J Invest Dermatol. 2002;119(6):1405-1410. doi: 10.1046/j.1523-1747.2002.19610.x

13. Zhou T, Elenitoba-Johnson KSJ. HLA-I aberrations in cutaneous T-cell lymphoma. Blood. 2025;145(3):252-253. doi: 10.1182/blood.2024027135

14. Willemze R. Primary cutaneous lymphoma: the 2018 update of the WHO-EORTC classification. Presse Med. 2022;51(1):104126. doi: 10.1016/j.lpm.2022.104126

15. Miyashiro D, Sanches JA. Mycosis fungoides and Sézary syndrome: clinical presentation, diagnosis, staging, and therapeutic management. Front Oncol. 2023;13:1141108. doi: 10.3389/fonc.2023.1141108

16. Khunger JM, Khunger N, Azad K, Srivastava S. Mycosis fungoides: a case report. Indian J Hematol Blood Transfus. 2010;26(1):12-14. doi: 10.1007/s12288-010-0004-8

17. He X, Zhang Q, Wang Y, et al. Non-coding RNAs in the spotlight of the pathogenesis, diagnosis, and therapy of cutaneous T cell lymphoma. Cell Death Discov. 2024;10(1):400. doi: 10.1038/s41420-024-02165-2

18. Stolearanco V, Narnini, MPJ, Hasselager SS et al. Cellular interactions and inflammation in the pathogenesis of cutaneous T-cell lymphoma. Front Cell Dev Biol. 2020;8:00851. doi: 10.3389/fcell.2020.00851.

19. Yamashita T, Abbade LP, Marques ME, Marques SA. Mycosis fungoides and Sézary syndrome: clinical, histopathological and immunohistochemical review and update. An Bras Dermatol. 2012;87(6):817-830. doi: 10.1590/S0365-05962012000600001

20. Zhuang TZ, McCook-Veal A, Switchenko J, et al. Characterizing outcomes in visceral cutaneous T-cell lymphoma: a single center retrospective study. Clin Lymphoma Myeloma Leuk. 2023;23(9):667-673. doi: 10.1016/j.clml.2023.05.001

21. Jairath NK, Bardhi R, Runge JS, et al. Predictors of large cell transformation in patients with Sézary syndrome: a retrospective analysis. PLoS ONE. 2022;17(11):e0277655. doi: 10.1371/journal.pone.0277655

22. Hristov AC, Tejasvi T, Wilcox RA. Cutaneous T-cell lymphomas: 2021 update on diagnosis, risk-stratification, and management. Am J Hematol. 2021;96(10):1313-1328. doi: 10.1002/ajh.26299

23. Li G, Chooback L, Wolfe JT, et al. Overexpression of p53 protein in cutaneous T cell lymphoma: relationship to large cell transformation and disease progression. J Invest Dermatol. 1998;110(5):767-770. doi: 10.1046/j.1523-1747.1998.00167.x

24. Gallardo F, Pujol RM. Genetics abnormalities with clinical impact in primary cutaneous lymphomas. Cancers. 2022;14(20):4972. doi: 10.3390/cancers14204972

25. da Silva Almeida AC, Abate F, Khiabanian H, et al. The mutational landscape of cutaneous T cell lymphoma and Sézary syndrome. Nat Genet. 2015;47(12):1465-1470. doi: 10.1038/ng.3442

26. Stolearenco V, Namini MRJ, Hasselager SS, et al. Cellular interactions and inflammation in the pathogenesis of cutaneous T-cell lymphoma. Front Cell Dev Biol. 2020;8:851. doi: 10.3389/fcell.2020.00851

27. Patil K, Kuttikrishnan S, Khan AQ, et al. Molecular pathogenesis of cutaneous T cell lymphoma: role of chemokines, cytokines, and dysregulated signaling pathways. Semin Cancer Biol. 2022;86(Pt 3):382-399. doi: 10.1016/j.semcancer.2021.12.003

28. Krejsgaard T, Lindahl LM, Mongan NP, et al. Malignant inflammation in cutaneous T-cell lymphoma—a hostile takeover. Semin Immunopathol. 2017;39(3):269-282. doi: 10.1007/s00281-016-0594-9

29. Nguyen CV, Bohjanen KA. Skin-directed therapies in cutaneous T-cell lymphoma. Dermatol Clin. 2015;33(4):683-696. doi: 10.1016/j.det.2015.05.004

30. Crimp C, Gangal A, Tarabadkar ES, et al. Mechlorethamine hydrochloride gel in the treatment of mycosis fungoides-type cutaneous T-cell lymphoma (MF-CTCL): a focus on patient selection and special considerations. Cancer Manag Res. 2022;14:3271-3279. doi: 10.2147/CMAR.S351420

31. Talpur R, Venkatarajan S, Duvic M. Mechlorethamine gel for the topical treatment of stage IA and IB mycosis fungoides-type cutaneous T-cell lymphoma. Expert Rev Clin Pharmacol. 2014;7(5):591-597. doi: 10.1586/17512433.2014.944500

32. Fujimura T, Amagai R, Kambayashi Y, Aiba S. Topical and systemic formulation options for cutaneous T cell lymphomas. Pharmaceutics. 2021;13(2):200. doi: 10.3390/pharmaceutics13020200

33. Tarabadkar ES, Shinohara MM. Skin directed therapy in cutaneous T-cell lymphoma. Front Oncol. 2019;9:260. doi: 10.3389/fonc.2019.00260

34. Carter J, Zug KA. Phototherapy for cutaneous T-cell lymphoma: online survey and literature review. J Am Acad Dermatol. 2009;60(1):39-50. doi: 10.1016/j.jaad.2008.08.043

35. Baron ED, Stevens SR. Phototherapy for cutaneous T-cell lymphoma. Dermatol Ther. 2003;16(4):303-310. doi: 10.1111/j.1396-0296.2003.01642.x

36. Rodriguez Suarez S, Pamies Andreu E, Muniz Grijalvo O, Garcia Morillo JS. Disfunción tiroidea y lipídica asociada a bexaroteno en el linfoma cutáneo de células T [Thyroid and lipidic dysfunction associated with bexarotene in cutaneous T-cell lymphoma]. Med Clin. 2016;146(3):117-120. doi: 10.1016/j.medcli.2015.07.017

37. Whittaker SJ, Foss FM. Efficacy and tolerability of currently available therapies for the mycosis fungoides and Sézary syndrome variants of cutaneous T-cell lymphoma. Cancer Treat Rev. 2007;33(2):146-160. doi: 10.1016/j.ctrv.2006.08.006

38. Prince HM, Dickinson M. Romidepsin for cutaneous T-cell lymphoma. Clin Cancer Res. 2012;18(13):3509-3515. doi: 10.1158/1078-0432.CCR-11-3144

39. Molgó M, Jaque A, Vial V, et al. Fotoféresis en el tratamiento de Síndrome de Sézary: caso clínico [Sézary syndrome treated with extracorporeal photopheresis: report of one case]. Rev Med Chil. 2015;143(11):1449-1458. doi: 10.4067/S0034-98872015001100011

40. Arulogun S, Prince HM, Gambell P, et al. Extracorporeal photopheresis for the treatment of Sézary syndrome using a novel treatment protocol. J Am Acad Dermatol. 2008;59(4):589-595. doi: 10.1016/j.jaad.2008.05.038

41. Anselmo AC, Mitragotri S. Nanoparticles in the clinic. Bioeng Transl Med. 2016;1(1):10-29. doi: 10.1002/btm2.10003

42. Baroli B. Penetration of nanoparticles and nanomaterials in the skin: fiction or reality? J Pharm Sci. 2010;99(1):21-50. doi: 10.1002/jps.21817

43. Horikoshi S, Serpone N. Introduction to nanoparticles. In: Microwaves in Nanoparticle Synthesis: Fundamentals and Applications. Weinheim, Germany: Wiley-VCH Verlag GmbH & Co. KGaA; 2013:1-24.

44. Ng KK, Zheng G. Molecular interactions in organic nanoparticles for phototheranostic applications. Chem Rev. 2015;115(19):11012-11042. doi: 10.1021/acs.chemrev.5b00140

45. Unnikrishnan G, Joy A, Megha M, et al. Exploration of inorganic nanoparticles for revolutionary drug delivery applications: a critical review. Discover Nano. 2023;18(1):157. doi: 10.1186/s11671-023-03943-0

46. Mura S, Nicolas J, Couvreur P. Stimuli-responsive nanocarriers for drug delivery. Nat Mater. 2013;12(11):991-1003. doi: 10.1038/nmat3776

47. Hunter P. Next-generation nanotech meds: diagnostic and therapeutic applications of non-organic nanoparticles are making their way into clinical use. EMBO Rep. 2017;18(1):25-27. doi: 10.15252/embr.201643694

48. De Jong WH, Borm PJ. Drug delivery and nanoparticles: applications and hazards. Int J Nanomed. 2008;3(2):133-149. doi: 10.2147/IJN.S596

49. Cho K, Wang X, Nie S, Chen ZG, Shin DM. Therapeutic nanoparticles for drug delivery in cancer. Clin Cancer Res. 2008;14(5):1310-1316. doi: 10.1158/1078-0432.CCR-07-1441

50. Bazak R, Houri M, El Achy S, Kamel S, Refaat T. Cancer active targeting by nanoparticles: a comprehensive review of literature. J Cancer Res Clin Oncol.2015;141(5):769-784. doi: 10.1007/s00432-014-1767-3

51. Byrne JD, Betancourt T, Brannon-Peppas L. Active targeting schemes for nanoparticle systems in cancer therapeutics. Adv Drug Deliv Rev. 2008;60(15):1615-1626. doi: 10.1016/j.addr.2008.08.005

52. Beach MA, Nayanathara U, Gao Y, et al. Polymeric nanoparticles for drug delivery. Chem Rev. 2024;124(9):5505-5616. doi: 10.1021/acs.chemrev.3c00705

53. Jiang W, Liang M, Lei Q, Li G, Wu S. The current status of photodynamic therapy in cancer treatment. Cancers. 2023;15(3):585. doi: 10.3390/cancers15030585

54. Abrahamse H, Hamblin MR. New photosensitizers for photodynamic therapy. Biochem J. 2016;473(4):347-364. doi: 10.1042/BJ20150942

55. Zhi D, Yang T, O’Hagan J, Zhang S, Donnelly RF. Photothermal therapy. J Control Release. 2020;325:52-71. doi: 10.1016/j.jconrel.2020.06.032

56. Riley RS, Day ES. Gold nanoparticle-mediated photothermal therapy: applications and opportunities for multimodal cancer treatment. Wiley Interdiscip Rev Nanomed Nanobiotechnol. 2017;9(4):e1449. doi: 10.1002/wnan.1449

57. Yang W, Liang H, Ma S, Wang D, Huang J. Gold nanoparticle based photothermal therapy: development and application for effective cancer treatment. Sustain Mater Technol. 2019;22:e00109. doi: 10.1016/j.susmat.2019.e00109

58. Deng R, Ji B, Yu H, et al. Multifunctional gold nanoparticles overcome microRNA regulatory network mediated-multidrug resistant leukemia. Sci Rep. 2019;9(1):5348.doi: 10.1038/s41598-019-41866-y

59. Mehtani D, Seth A, Sharma P, et al. Biomaterials for sustained and controlled delivery of small drug molecules. In: Tekade RK, editor. Biomaterials and Bionanotechnology. Academic Press; 2019:89-152. doi: 10.1016/B978-0-12-814427-5.00004-4

60. Huang X, El-Sayed IH, Qian W, El-Sayed MA. Cancer cell imaging and photothermal therapy in the near-infrared region by using gold nanorods. J Am Chem Soc. 2006;128(6):2115-2120. doi: 10.1021/ja057254a

61. Cai W, Gao T, Hong H, Sun J. Applications of gold nanoparticles in cancer nanotechnology. Nanotechnol Sci Appl. 2008;1:17-32. doi: 10.2147/NSA.S3788

62. Shakil MS, Niloy MS, Mahmud KM, et al. Theranostic potentials of gold nanomaterials in hematological malignancies. Cancers. 2022;14(13):3047. doi: 10.3390/cancers14133047

63. Choudhary S, Kaur S, Gandhi H, et al. An updated review on the potential of gold nanoparticles for cancer treatment and detection. Gold Bull. 2025;58:4. doi: 10.1007/s13404-025-00357-x

64. Li B, Yakufu M, Xie R, et al. Functional gold nanoparticles in diagnosis and treatment of cancer: a systematic review. APL Mater. 2025;13(5):050602. doi: 10.1063/5.0273264

65. Dastgheib ZS, Abolmaali SS, Farahavar G, et al. Gold nanostructures in melanoma: advances in treatment, diagnosis, and theranostic applications. Heliyon. 2024;10(15):e35655. doi: 10.1016/j.heliyon.2024.e35655

66. Zamora-Pérez P, She Q, Santos HD, et al. Two photon-responsive gold nano-capsules enable targeted photothermal hyperthermia of chemoresistant melanoma: injectionroute-dependent efficacy and renal evidence of fragment clearance. J Mater Chem B. 2025;13:9498-9511. doi: 10.1039/d5tb00167f

67. Sang D, Luo X, Liu J. Biological interaction and imaging of ultrasmall gold nanoparticles. Nano Micro Lett. 2024;16(1):44. doi: 10.1007/s40820-023-01266-4

68. Gomes SM, Gaspar MM, Coelho JM, Reis CP. Targeting superficial cancers with gold nanoparticles: a review of current research. Ther Deliv. 2024;15(10):781-799. doi: 10.1080/20415990.2024.2395249

69. Badir A, Refki S, Sekkat Z. Utilizing gold nanoparticles in plasmonic photothermal therapy for cancer treatment. Heliyon. 2025;11(4):e42738. doi: 10.1016/j.heliyon.2025.e42738

70. Nel AE, Mädler L, Velegol D, et al. Understanding biophysicochemical interactions at the nano-bio interface. Nat Mater. 2009;8(7):543-557. doi: 10.1038/nmat2442

71. Nguyenova HY, Hubalek Kalbacova M, Dendisova M, et al. Stability and biological response of PEGylated gold nanoparticles. Heliyon. 2024;10(9):e30601. doi: 10.1016/j.heliyon.2024.e30601

72. Schrand AM, Rahman MF, Hussain SM, et al. Metal-based nanoparticles and their toxicity assessment. Wiley Interdiscip Rev Nanomed Nanobiotechnol. 2010;2(5):544-568. doi: 10.1002/wnan.103

73. Vigata M, Meinert C, Hutmacher DW, Bock N. Hydrogels as drug delivery systems: a review of current characterization and evaluation techniques. Pharmaceutics. 2020;12(12):1188. doi: 10.3390/pharmaceutics12121188

74. Kim YH. What factors guide treatment selection in mycosis fungoides and Sézary syndrome? Hematology Am Soc Hematol Educ Program. 2021;2021(1):303-312. doi: 10.1182/hematology.2021000263

75. Latzka J, Assaf C, Bagot M, et al. EORTC consensus recommendations for the treatment of mycosis fungoides/Sézary syndrome—update 2023. Eur J Cancer. 2023;195:113343. doi: 10.1016/j.ejca.2023.113343

76. Ahmed EM. Hydrogel: preparation, characterization, and applications: a review. J Adv Res. 2015;6(2):105-121. doi: 10.1016/j.jare.2013.07.006

77. Peppas NA, Hilt JZ, Khademhosseini A, Langer R. Hydrogels in biology and medicine: from molecular principles to bio-nanotechnology. Adv Mater. 2006;18(11):1345-1360. doi: 10.1002/adma.200501612

78. Richbourg N, Peppas NA. The swollen polymer network hypothesis: quantitative models of hydrogel swelling, stiffness, and solute transport. Prog Polym Sci. 2020;105:101243. doi: 10.1016/j.progpolymsci.2020.101243

79. Kim SJ, Park S, Kim SI. Swelling behavior of interpenetrating polymer network hydrogels composed of poly(vinyl alcohol) and chitosan. React Funct Polym. 2003;55:53-59. doi: 10.1016/S1381-5148(02)00214-6

80. Jia D, Muthukumar M. Theory of charged gels: swelling, elasticity, and dynamics. Gels. 2021;7(2):49. doi: 10.3390/gels7020049

81. Briggs F, Browne D, Asuri P. Role of polymer concentration and crosslinking density on release rates of small molecule drugs. Int J Mol Sci. 2022;23(8):4118. doi: 10.3390/ijms23084118

82. Urena-Amate MD, Socias-Viciana MDM, Urbano-Juan MDM, García-Alcaraz MDC. Effects of pH and crosslinking agent in the evaluation of hydrogels as potential nitrate-controlled release systems. Polymers. 2023;15(5):1246. doi: 10.3390/polym15051246

83. Peppas NA, Huang Y, Torres-Lugo M, Ward JH, Zhang J. Physicochemical foundations and structural design of hydrogels in medicine and biology. Annu Rev Biomed Eng. 2000;2:9-29. doi: 10.1146/annurev.bioeng.2.1.9

84. Rizwan M, Yahya R, Hassan A, et al. pH sensitive hydrogels in drug delivery: brief history, properties, swelling, and release mechanism, material selection and applications. Polymers. 2017;9(4):137. doi: 10.3390/polym9040137

85. Fallingborg J, Christensen LA, Ingeman-Nielsen M, et al. Measurement of gastrointestinal pH and regional transit times in normal children. J Pediatr Gastroenterol Nutr. 1990;11(2):211-214. doi: 10.1097/00005176-199008000-00010

86. Hua S. Advances in oral drug delivery for regional targeting in the gastrointestinal tract—Influence of physiological, pathophysiological and pharmaceutical factors. Front Pharmacol. 2020;11:524. doi: 10.3389/fphar.2020.00524

87. Marim B, Pereira J, Andrello A, Mali S. Starch-cellulose-gelatin hydrogels obtained by reactive extrusion aiming an ecologically friendly perspective. Res Sq. Preprint online 2023. doi: 10.21203/rs.3.rs-3755080/v1

88. Lanzalaco S, Armelin E. Poly(N-isopropylacrylamide) and copolymers: a review on recent progresses in biomedical applications. Gels. 2017;3(4):36. doi: 10.3390/gels3040036

89. Ansari MJ, Rajendran RR, Mohanto S, et al. Poly(Nisopropylacrylamide)-based hydrogels for biomedical applications: a review of the state-of-the-art. Gels. 2022;8(7):454. doi: 10.3390/gels8070454

90. Nasseri R, Deutschman C, Han L, Pope M, Tam KC. Cellulose nanocrystals in smart and stimuli-responsive materials: a review. Mater Today Adv. 2020;5:100055. doi: 10.1016/j.mtadv.2020.100055

91. Ková? J, Priš?áková P, Gbelcová H, et al. Bioadhesive and injectable hydrogels and their correlation with mesenchymal stem cells differentiation for cartilage repair: a mini-review. Polymers. 2023;15(21):4228. doi: 10.3390/polym15214228

92. Bovone G, Dudaryeva OY, Marco-Dufort B, Tibbitt MW. Engineering hydrogel adhesion for biomedical applications via chemical design of the junction. ACS Biomater Sci Eng. 2021;7(9):4048-4076. doi: 10.1021/acsbiomaterials.0c01677

93. Yao H, Wu M, Lin L, et al. Design strategies for adhesive hydrogels with natural antibacterial agents as wound dressings: status and trends. Mater Today Bio. 2022;16:100429. doi: 10.1016/j.mtbio.2022.100429

94. Renvoise J, Burlot D, Marin G, Derail C. Adherence performances of pressure sensitive adhesives on a model viscoelastic synthetic film: a tool for the understanding of adhesion on the human skin. Int J Pharm. 2009;368(1-2):83-88. doi: 10.1016/j.ijpharm.2008.09.056

95. Cilurzo F, Gennari CG, Minghetti P. Adhesive properties: a critical issue in transdermal patch development. Expert Opin Drug Deliv. 2012;9(1):33-45. doi: 10.1517/17425247.2012.637107

96. Gutschke E, Bracht S, Nagel S, Weitschies W. Adhesion testing of transdermal matrix patches with a probe tack test—in vitro and in vivo evaluation. Eur J Pharm Biopharm. 2010;75(3):399-404. doi: 10.1016/j.ejpb.2010.03.016

97. Bird D, Ravindra N. Transdermal drug delivery and patches—an overview. Med Devices Sens. 2020;3:e10069. doi: 10.1002/mds3.10069

98. Eiler J, Hansen D, Bingöl B, et al. In vitro evaluation of skin adhesives during perspiration. Int J Adhes Adhes. 2020;99:102574. doi: 10.1016/j.ijadhadh.2020.102574

99. Gudin J, Webster LR, Greuber E, et al. Open-label adhesion performance studies of a new lidocaine topical system 1.8% versus lidocaine patches 5% and lidocaine medicated plaster 5% in healthy subjects. J Pain Res. 2021;14:513-526. doi: 10.2147/JPR.S287153

100. Dyson E, Sikkink S, Nocita D, et al. Evaluating the irritant factors of silicone and hydrocolloid skin contact adhesives using trans-epidermal water loss, protein stripping, erythema, and ease of removal. ACS Appl Bio Mater. 2024;7(1):284-296. doi: 10.1021/acsabm.3c00874

101. Mbithi F, Worsley PR. Adhesives for medical application: peel strength testing and evaluation of biophysical skin response. J Mech Behav Biomed Mater. 2023;148:106168. doi: 10.1016/j.jmbbm.2023.106168

102. Stone R II, Wall JT, Natesan S, et al. PEG-plasma hydrogels increase epithelialization using a human ex vivo skin model. Int J Mol Sci. 2018;19(10):3156. doi: 10.3390/ijms19103156

103. Shen Z, Cao Y, Li M, et al. Construction of tissue-engineered skin with rete ridges using co-network hydrogels of gelatin methacrylated and poly(ethylene glycol) diacrylate. Mater Sci Eng C. 2021;129. doi: 10.1016/j.msec.2021.112360

104. Venkatesh M, Barathi VA, Goh ETL, et al. Antimicrobial activity and cell selectivity of synthetic and biosynthetic cationic polymers. Antimicrob Agents Chemother. 2017;61(10):e00469-17. doi: 10.1128/AAC.00469-17

105. Sabnis A, Rahimi M, Chapman C, et al. Cytocompatibility studies of an in situ photopolymerized thermos-responsive hydrogel nanoparticle system using human aortic smooth muscle cells. J Biomed Mater Res A. 2009;91(1):52-59. doi: 10.1002/jbm.a.32194

106. Tomal W, Petko F, Ga?ek M, et al. Water-soluble type I radical photo-initiators dedicated to obtaining microfabricated hydrogels. Chem Mater. 2024;36(13):6421-6439. doi: 10.1021/acs.chemmater.4c00369

107. Guyot C, Malaret T, Touani Kameni F, Cerruti M, Lerouge S. How to design catechol-containing hydrogels for cell encapsulation despite catechol toxicity. ACS Appl Bio Mater. 2023;6(7):2875-2885. doi: 10.1021/acsabm.3c00306

108. de Groot A, van Oers EM, Ipenburg NA, et al. Allergic contact dermatitis caused by glucose sensors and insulin pumps: a full review. Part 1: sensors and pumps, adverse cutaneous reactions, allergens, and diabetes devices causing allergic contact dermatitis. Contact Dermat. 2025;92(2):87-112. doi: 10.1111/cod.14698

109. Mowitz M, Fornander L, Hosseiny S, et al. Patch testing with isobornyl acrylate in 16 Swedish patients with contact dermatitis from glucose sensors and/or insulin pumps. Acta Derm Venereol. 2019;99(13):1286-1287. doi: 10.2340/00015555-3256

110. Arabpour Z, Abedi F, Salehi M, et al. Hydrogel-based skin regeneration. Int J Mol Sci. 2024;25(4):1982. doi: 10.3390/ijms25041982

111. Li J, Mooney DJ. Designing hydrogels for controlled drug delivery. Nat Rev Mater. 2016;1(12):16071. doi: 10.1038/natrevmats.2016.71

112. Sun JY, Zhao X, Illeperuma WR, et al. Highly stretchable and tough hydrogels. Nature. 2012;489(7414):133-136. doi: 10.1038/nature11409

113. Bin Imran A, Esaki K, Gotoh H, et al. Extremely stretchable thermosensitive hydrogels by introducing slide-ring polyrotaxane cross-linkers and ionic groups into the polymer network. Nat Commun. 2014;5:5124. doi: 10.1038/ncomms6124

114. Jiang L, Liu C, Mayumi K, Kato K, Yokoyama H, Ito K. Highly stretchable and instantly recoverable slide-ring gels consisting of enzymatically synthesized polyrotaxane with low host coverage. Chem Mater. 2018;30(15):5013-5019. doi: 10.1021/acs.chemmater.8b01208

115. Sun TL, Luo F, Kurokawa T, Karobi SN, Nakajima T, Gong JP. Molecular structure of self-healing polyampholyte hydrogels analyzed from tensile behaviors. Soft Matter. 2015;11(48):9355-9366. doi: 10.1039/c5sm01423a

116. Caccavo D, Vietri A, Lamberti G, Barba AA, Larsson A. Modeling the mechanics and the transport phenomena in hydrogels. In: Manca D, ed. Quantitative Systems Pharmacology: Models and Model-Based Systems with Applications. Computer Aided Chemical Engineering. Amsterdam, Netherlands: Elsevier; 2018;42:357-383. doi: 10.1016/B978-0-444-63964-6.00012-X

117. Prausnitz MR, Langer R. Transdermal drug delivery. Nat Biotechnol. 2008;26(11):1261-1268. doi: 10.1038/nbt.1504

118. He J, Zhang Y, Yu X, et al. Wearable patches for transdermal drug delivery. Acta Pharm Sin B. 2023;13(6):2298-2309. doi: 10.1016/j.apsb.2023.05.009

119. Gupta N, Gupta GD, Singh D. Localized topical drug delivery systems for skin cancer: current approaches and future prospects. Front Nanotechnol. 2022;4:1006628. doi: 10.3389/fnano.2022.1006628

120. Benson HAE, Grice JE, Mohammed Y, et al. Topical and transdermal drug delivery: from simple potions to smart technologies. Curr Drug Deliv. 2019;16(5):444-460. doi: 10.2174/1567201816666190201143457

121. Nuutila K, Eriksson E. Moist wound healing with commonly available dressings. Adv Wound Care. 2021;10(12):685-698. doi: 10.1089/wound.2020.1232

122. Machado RL, Gomes AC, Marques EF. Hydrogels as versatile colloidal platforms to combat skin cancer – Physicochemical features, strategies and advances. J Mol Liq. 2024;416:126453. doi: 10.1016/j.molliq.2024.126453

123. Courtenay AJ, McAlister E, McCrudden MTC, et al. Hydrogel-forming microneedle arrays as a therapeutic option for transdermal esketamine delivery. J Control Release. 2020;322:177-186. doi: 10.1016/j.jconrel.2020.03.026

124. Donnelly RF, McCrudden MTC, Alkilani AZ, et al. Hydrogel-forming microneedles prepared from “super swelling” polymers combined with lyophilised wafers for transdermal drug delivery. PLoS ONE. 2014;9(10):e111547. doi: 10.1371/journal.pone.0111547.

125. Zhu L, Qiao G, Gao H, et al. Enhancing melanoma therapy with hydrogel microneedles. Front Oncol. 2025;15:1590534. doi: 10.3389/fonc.2025.1590534.

126. Zhang Z, Zhang Z, Zeng W, Li Y, Zhu C. A hyaluronic acid-based dual-functional hydrogel microneedle system for sequential melanoma ablation and skin regeneration. Int J Biol Macromol. 2024;283:138039. doi: 10.1016/j.ijbiomac.2024.138039

127. He W, Zhang Y, Qu Y, et al. Research progress on hydrogel-based drug therapy in melanoma immunotherapy. BMB Rep. 2024;57(2):71-78. doi: 10.5483/BMBRep.2023-0160

128. Liu B, Chen K. Advances in hydrogel-based drug delivery systems. Gels. 2024;10(4):262. doi: 10.3390/gels10040262

129. Sibuyi NRS, Moabelo KL, Fadaka AO, et al. Multifunctional gold nanoparticles for improved diagnostic and therapeutic applications: a review. Nanoscale Res Lett. 2021;16(1):174. doi: 10.1186/s11671-021-03632-w

130. Khan MS, Vishakante GD, Siddaramaiah H. Gold nanoparticles: a paradigm shift in biomedical applications. Adv Colloid Interface Sci. 2013;199-200:44-58. doi: 10.1016/j.cis.2013.06.003

131. Huang H, Liu R, Yang J, et al. Gold nanoparticles: construction for drug delivery and application in cancer immunotherapy. Pharmaceutics. 2023;15(7):1868. doi: 10.3390/pharmaceutics15071868

132. Yoon MS, Lee JM, Jo MJ, et al. Dual-drug delivery systems using hydrogel–nanoparticle composites: recent advances and key applications. Gels. 2025;11(7):520. doi: 10.3390/gels11070520

133. Meng H, Zhao Y, Cai H, et al. Hydrogels containing chitosan-modified gold nanoparticles show significant efficacy in healing diabetic wounds infected with antibiotic-resistant bacteria. Int J Nanomed. 2024;19:1539-1556. doi: 10.2147/IJN.S448282

134. Gounden V, Singh M. Gold nanoparticle-based hydrogel: application in anticancer drug delivery and wound healing in vitro. Pharmaceutics. 2025;17(5):633. doi: 10.3390/pharmaceutics17050633

135. Kim HS, Lee DY. Near-infrared–responsive cancer photothermal and photodynamic therapy using gold nanoparticles. Polymers. 2018;10(9):961. doi: 10.3390/polym10090961

136. Bai X, Wang Y, Song Z, Feng Y, Chen Y, Zhang D, Feng L. The basic properties of gold nanoparticles and their applications in tumor diagnosis and treatment. Int J Mol Sci. 2020;21(7):2480. doi: 10.3390/ijms21072480

137. Koga K, Tagami T, Ozeki T. Gold nanoparticle-coated thermosensitive liposomes for the triggered release of doxorubicin and photothermal therapy using a near-infrared laser. Colloids Surf A Physicochem Eng Asp. 2021;626:127038. doi: 10.1016/j.colsurfa.2021.127038

138. Zhang Y, Zhan X, Xiong J, et al. Temperature-dependent cell death patterns induced by functionalized gold nanoparticle photothermal therapy in melanoma cells. Sci Rep. 2018;8(1):8720. doi: 10.1038/s41598-018-26978-1

139. Anzengruber F, Avci P, de Freitas LF, Hamblin MR. T-cell–mediated antitumor immunity after photodynamic therapy: why does it not always work and how can we improve it? Photochem Photobiol Sci. 2015;14(8):1492-1509. doi: 10.1039/c4pp00455h

140. Xie M, Gong T, Wang Y, et al. Advancements in photothermal therapy using near-infrared light for bone tumors. Int J Mol Sci. 2024;25(8):4139. doi: 10.3390/ijms25084139

141. Saha S, Taneja M, Dubey S, Bhardwaj A. Unlocking the potential of gold nanoparticles as a game-changer in the fight against hepatocellular carcinoma. Explor Med. 2025;6:1001272. doi: 10.37349/emed.2025.1001272

142. Chu KS, Schorzman AN, Finniss MC, et al. Nanoparticle drug loading as a design parameter to improve docetaxel pharmacokinetics and efficacy. Biomaterials. 2013;34(33):8424-8429. doi: 10.1016/j.biomaterials.2013.07.038

143. Shen S, Wu Y, Liu Y, Wu D. High drug-loading nanomedicines: progress, current status, and prospects. Int J Nanomed. 2017;12:4085-4109. doi: 10.2147/IJN.S132780

144. Dykman L, Khlebtsov B, Khlebtsov N. Drug delivery using gold nanoparticles. Adv Drug Deliv Rev. 2025;216:115481. doi: 10.1016/j.addr.2024.115481

145. He X, Yang Y, Han Y, et al. Extracellular matrix physical properties govern the diffusion of nanoparticles in tumor microenvironment. Proc Natl Acad Sci USA. 2023;120(1):e2209260120. doi: 10.1073/pnas.2209260120

146. Lin CC, Metters AT. Hydrogels in controlled release formulations: network design and mathematical modeling. Adv Drug Deliv Rev. 2006;58(12-13):1379-1408. doi: 10.1016/j.addr.2006.09.004

147. Wang J, Yang Y, Yu M, Hu G, Gan Y, Gao H, Shi X. Diffusion of rod-like nanoparticles in non-adhesive and adhesive porous polymeric gels. J Mech Phys Solids. 2018;112:431-457. doi: 10.1016/j.jmps.2017.12.014

148. Thomas RG, Surendran SP, Jeong YY. Tumor microenvironment–stimuli responsive nanoparticles for anticancer therapy. Front Mol Biosci. 2020;7:610533. doi: 10.3389/fmolb.2020.610533

149. Poomrattanangoon S, Pissuwan D. Gold nanoparticles coated with collagen-I and their wound healing activity in human skin fibroblast cells. Heliyon. 2024;10(13):e33302. doi: 10.1016/j.heliyon.2024.e33302

150. Rajinikanth SB, Rajkumar DS, Keerthika K, Vijayaragavan V. Chitosan-based biomaterial in wound healing: a review. Cureus. 2024;16(2):e55193. doi: 10.7759/cureus.55193

151. Kearney CJ, Skaat H, Kennedy SM, Hu J, Darnell M, Raimondo TM, et al. Switchable release of entrapped nanoparticles from alginate hydrogels. Adv Healthc Mater. 2015;4(11):1634-1639. doi: 10.1002/adhm.201500254

152. Park HH, Lee TR. Thermo- and pH-responsive hydrogel-coated gold nanoparticles prepared from rationally designed surface-confined initiators. J Nanopart Res. 2011;13(7):2909-2918. doi: 10.1007/s11051-010-0180-3

153. Duncan B, Kim C, Rotello VM. Gold nanoparticle platforms as drug and biomacromolecule delivery systems. J Control Release. 2010;148(1):122-127. doi: 10.1016/j.jconrel.2010.06.004

154. Thoniyot P, Tan MJ, Karim AA, Young DJ, Loh XJ. Nanoparticle–hydrogel composites: concept, design, and applications of these promising, multi-functional materials. Adv Sci. 2015;2(1-2):1400010. doi: 10.1002/advs.201400010.

155. Dannert C, Stokke BT, Dias RS. Nanoparticle-hydrogel composites: from molecular interactions to macroscopic behavior. Polymers. 2019;11(2):275. doi: 10.3390/polym11020275

156. Singpanna K, Pornpitchanarong C, Patrojanasophon P, et al. Gold nanoparticles and their applications in transdermal drug delivery: a review. J Drug Deliv Sci Technol. 2023;90:105174. doi: 10.1016/j.jddst.2023.105174

157. Yeh YC, Creran B, Rotello VM. Gold nanoparticles: preparation, properties, and applications in bio-nanotechnology. Nanoscale. 2012;4(6):1871-1880. doi: 10.1039/c1nr11188d

158. Willemze R, Cerroni L, Kempf W, et al. The 2018 update of the WHO-EORTC classification for primary cutaneous lymphomas. Blood. 2019;133(16):1703-1714. doi: 10.1182/blood-2018-11-881268

159. Lai YJ, Ting PJ, Yang SJ, et al. Injectable NIR-II-responsive nanocomposite hydrogels containing gold nanoparticle-decorated carbon nanotubes for controllable drug delivery and tumor therapy. Acta Biomater. 2026;209:225-240. doi: 10.1016/j.actbio.2025.11.050

160. El-Sayed N, Elbadri K, Correia A, Santos HA. Polyethylene glycol-stabilized gold nanostars-loaded microneedles for photothermal therapy of melanoma. Adv Mater Technol. 2023;8:2301159. doi: 10.1002/admt.202301159

161. Chen WH, Yang CX, Qiu WX, et al. Multifunctional theranostic nanoplatform for cancer combined therapy based on gold nanorods. Adv Healthc Mater. 2015;4(15):2247-2259. doi: 10.1002/adhm.201500453

162. Dong L, Li Y, Li Z, et al. Au Nanocage-Strengthened Dissolving Microneedles for Chemo-Photothermal Combined Therapy of Superficial Skin Tumors. ACS Appl Mater Interfaces. 2018;10(11):9247-9256. doi: 10.1021/acsami.7b18293

163. He H, Fei Z, Guo T, et al. Bioadhesive injectable hydrogel with phenolic carbon quantum dot supported Pd single atom nanozymes as a localized immunomodulation niche for cancer catalytic immunotherapy. Biomaterials. 2022;280:121272.

164. Vines JB, Yoon JH, Ryu NE, Lim DJ, Park H. Gold nanoparticles for photothermal cancer therapy. Front Chem. 2019;7:167. doi: 10.3389/fchem.2019.00167

165. Chao-Lo MP, King-Ismael D, Lopez RA. Primary cutaneous CD30+ anaplastic large cell lymphoma: report of a rare case. J Dermatol Case Rep. 2008;2(3):31-34. doi: 10.3315/jdcr.2008.1013

166. Fan M, Han Y, Gao S, et al. Ultrasmall gold nanoparticles in cancer diagnosis and therapy. Theranostics. 2020;10(11):4944-4957. doi: 10.7150/thno.42471

167. Dreaden EC, Alkilany AM, Huang X, Murphy CJ, El-Sayed MA. The golden age: gold nanoparticles for biomedicine. Chem Soc Rev. 2012;41(7):2740-2779. doi: 10.1039/c1cs15237h

168. Henderson TA, Morries LD. Near-infrared photonic energy penetration: can infrared phototherapy effectively reach the human brain? Neuropsychiatr Dis Treat. 2015;11:2191-2208. doi: 10.2147/NDT.S78182

169. Domb AJ, Sharifzadeh G, Nahum V, Hosseinkhani H. Safety Evaluation of Nanotechnology Products. Pharmaceutics. 2021; 13(10):1615. doi: 10.3390/pharmaceutics13101615

170. Majeri? P, Jovi? Z, Švarc T, et al. Physicochemical properties of gold nanoparticles for skin care creams. Materials. 2023;16(8):3011. doi: 10.3390/ma16083011

171. Hou J, Li B, Jang W, Yun J, Eyimegwu FM, Kim J-H. Integration of Gold Nanoparticles into Crosslinker-Free Polymer Particles and Their Colloidal Catalytic Property. Nanomaterials. 2023; 13(3):416. doi: 10.3390/nano13030416

172. Chan H, Král P. Nanoparticles self-assembly within lipid bilayers. ACS Omega. 2018;3(9):10631-10637. doi: 10.1021/acsomega.8b01445

173. Bailly AL, Correard F, Popov A, et al. In vivo evaluation of safety, biodistribution and pharmacokinetics of laser-synthesized gold nanoparticles. Sci Rep. 2019;9(1):12890. doi: 10.1038/s41598-019-48748-3

174. Li X, Hu Z, Ma J, et al. The systematic evaluation of size-dependent toxicity and multi-time biodistribution of gold nanoparticles. Colloids Surf B Biointerfaces. 2018;167:260-266. doi: 10.1016/j.colsurfb.2018.04.005

175. Wong AC, Wright DW. Size-dependent cellular uptake of DNA functionalized gold nanoparticles. Small. 2016;12(40):5592-5600. doi: 10.1002/smll.201601697

176. Huang R, Carney RP, Ikuma K, Stellacci F, Lau BLT. Effects of surface compositional and structural heterogeneity on nanoparticle-protein interactions: different protein configurations. ACS Nano. 2014;8(6):5402-5412. doi: 10.1021/nn501203k

177. Jiang Y, Huo S, Mizuhara T, et al. The interplay of size and surface functionality on the cellular uptake of sub-10 nm gold nanoparticles. ACS Nano. 2015;9(10):9986-9993. doi: 10.1021/acsnano.5b03521

178. van Pomeren M, Peijnenburg WJGM, Vlieg RC, van Noort SJT, Vijver MG. The biodistribution and immuno-responses of differently shaped non-modified gold particles in zebrafish embryos. Nanotoxicology. 2019;13(4):558-571. doi: 10.1080/17435390.2018.1564079

179. Turánek J, Knötigová PT, Kulich P, et al. Preparation and complex characterisation of stabilised gold nanoparticles: biodistribution and application for high resolution in vivo imaging. Pharmaceuticals. 2024;17(11):1479. doi: 10.3390/ph17111479

180. Yao L, Bojic D, Liu M. Applications and safety of gold nanoparticles as therapeutic devices in clinical trials. J Pharm Anal. 2023;13(9):960-967. doi: 10.1016/j.jpha.2023.06.001

181. Jakic K, Selc M, Razga F, et al. Long-term accumulation, biological effects and toxicity of BSA-coated gold nanoparticles in the mouse liver, spleen, and kidneys. Int J Nanomedicine. 2024;19:4103-4120. doi: 10.2147/IJN.S443168

182. Ozcicek I, Aysit N, Cakici C, Aydeger A. The effects of surface functionality and size of gold nanoparticles on neuronal toxicity, apoptosis, ROS production and cellular/suborgan biodistribution. Mater Sci Eng C. 2021;128:112308. doi: 10.1016/j.msec.2021.112308

183. Ji J, Sun J, Zhang Y, Sun X. Cell-based metabolomics approach for anticipating and investigating cytotoxicity of gold nanorods. Foods. 2022;11(22):3569. doi: 10.3390/foods11223569

184. El-Baz N, Nunn BM, Bates PJ, O’Toole MG. The impact of PEGylation on cellular uptake and in vivo biodistribution of gold nanoparticle MRI contrast agents. Bioengineering. 2022;9(12):766. doi: 10.3390/bioengineering9120766

185. Shi D, Beasock D, Fessler A, et al. To PEGylate or not to PEGylate: immunological properties of nanomedicine’s most popular component, polyethylene glycol and its alternatives. Adv Drug Deliv Rev. 2022;180:114079. doi: 10.1016/j.addr.2021.114079

186. ?or?evi? S, Gonzalez MM, Conejos-Sánchez I, et al. Current hurdles to the translation of nanomedicines from bench to the clinic. Drug Deliv Transl Res. 2022;12(3):500-525. doi: 10.1007/s13346-021-01024-2

187. Duvic M, Pinter-Brown LC, Foss FM, et al. Phase 1/2 study of mogamulizumab, a defucosylated anti-CCR4 antibody, in previously treated patients with cutaneous T-cell lymphoma. Blood. 2015;125(12):1883-1889. doi: 10.1182/blood-2014-09-600924

188. Deen GR. Toxicity, regulatory considerations, and commercialization aspects of multi-component hydrogels. In: Dodda JM, Deshmukh K, Bezuidenhout D, editors. Multicomponent Hydrogels: Smart Materials for Biomedical Applications. The Royal Society of Chemistry; 2023:604-635. doi: 10.1039/BK9781837670055-00604

189. He B, Sui X, Yu B, Wang S, Shen Y, Cong H. Recent advances in drug delivery systems for enhancing drug penetration into tumors. Drug Deliv. 2020;27(1):1474-1490. doi: 10.1080/10717544.2020.1831106

190. Gill RPK, Gantchev J, Martínez Villarreal A, et al. Understanding cell lines, patient-derived xenograft and genetically engineered mouse models used to study cutaneous T-cell lymphoma. Cells. 2022;11(4):593. doi: 10.3390/cells11040593

191. Ga?anin J, Synatschke CV, Weil T. Biomedical applications of DNA-based hydrogels. Adv Funct Mater. 2020;30(4):1906253. doi: 10.1002/adfm.201906253

192. Nakamura N, Ohta S. Precise control methods of the physicochemical properties of nanoparticles for personalized medicine. Curr Opin Biotechnol. 2024;87:103108. doi: 10.1016/j.copbio.2024.103108

193. Luna DE, Shinohara MM. New molecular and biological markers in cutaneous T cell lymphoma: therapeutic implications. Curr Hematol Malig Rep. 2023;18(3):83-88. doi: 10.1007/s11899-023-00692-w